Citi Upgrades Dimension Therapeutics (DMTX) to Neutral (Yesterday)

Citi upgraded Dimension Therapeutics (NASDAQ: DMTX) from Sell to Neutral with a price target of $6.00 (from $5.50).

Analyst Joel Beatty believes the acquisition from Ultragenyx Pharma (NASDAQ: RARE) is likely to happen and states there is no reason for it not to. The analyst also believes there will not be a competing offer.

For an analyst ratings summary and ratings history on Dimension Therapeutics click here. For more ratings news on Dimension Therapeutics click here.

Shares of Dimension Therapeutics closed at $5.90 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• New Street Research Upgrades Micron Technology (MU) to Buy
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform